Everolimus therapy for progressive adrenocortical cancer.
Patients with advanced adrenocortical carcinoma (ACC) have limited treatment options after failure of chemotherapy. Tumor IGF2 expression has been shown to be amplified in the majority of cases of ACC and autocrine/paracrine activation of the IGF receptor (IGF-R) is thought to play a major role in t...
Asıl Yazarlar: | Fraenkel, M, Gueorguiev, M, Barak, D, Salmon, A, Grossman, AB, Gross, D |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
2013
|
Benzer Materyaller
-
Everolimus therapy for progressive adrenocortical cancer
Yazar:: Fraenkel, M, ve diğerleri
Baskı/Yayın Bilgisi: (2013) -
Adrenocortical Cancer: A Therapeutic Approach with Everolimus (RAD001)
Yazar:: Gueorguiev, M, ve diğerleri
Baskı/Yayın Bilgisi: (2010) -
Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
Yazar:: Druce, MR, ve diğerleri
Baskı/Yayın Bilgisi: (2009) -
Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma
Yazar:: Druce, M, ve diğerleri
Baskı/Yayın Bilgisi: (2012) -
Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma.
Yazar:: Druce, M, ve diğerleri
Baskı/Yayın Bilgisi: (2012)